Avadel Pharmaceuticals Valuation
| AVDL Stock | USD 11.66 0.91 8.47% |
At this time, the firm appears to be undervalued. Avadel Pharmaceuticals shows a prevailing Real Value of $14.84 per share. The current price of the firm is $11.66. Our model approximates the value of Avadel Pharmaceuticals from analyzing the firm fundamentals such as return on equity of -1.0, and Profit Margin of (1.12) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Avadel Pharmaceuticals' valuation include:
Price Book 15.0486 | Enterprise Value 1.1 B | Enterprise Value Ebitda (6.43) | Price Sales 8.1324 | Forward PE 17.3913 |
Undervalued
Today
Please note that Avadel Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Avadel Pharmaceuticals is based on 3 months time horizon. Increasing Avadel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Avadel stock is determined by what a typical buyer is willing to pay for full or partial control of Avadel Pharmaceuticals PLC. Since Avadel Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Avadel Stock. However, Avadel Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.66 | Real 14.84 | Target 19.89 | Hype 11.49 | Naive 9.28 |
The intrinsic value of Avadel Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Avadel Pharmaceuticals' stock price.
Estimating the potential upside or downside of Avadel Pharmaceuticals PLC helps investors to forecast how Avadel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Avadel Pharmaceuticals more accurately as focusing exclusively on Avadel Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Avadel Pharmaceuticals' intrinsic value based on its ongoing forecasts of Avadel Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Avadel Pharmaceuticals' closest peers.
Avadel Pharmaceuticals Cash |
|
Avadel Valuation Trend
Knowing Avadel Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Avadel Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Avadel Revenue by Product
Avadel Pharmaceuticals Total Value Analysis
Avadel Pharmaceuticals PLC is presently forecasted to have valuation of 1.06 B with market capitalization of 1.27 B, debt of 35.38 M, and cash on hands of 104.12 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Avadel Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.06 B | 1.27 B | 35.38 M | 104.12 M |
Avadel Pharmaceuticals Investor Information
About 80.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.07. Avadel Pharmaceuticals recorded a loss per share of 1.09. The entity had not issued any dividends in recent years. Based on the key indicators related to Avadel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Avadel Pharmaceuticals PLC is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Avadel Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Avadel Pharmaceuticals has an asset utilization ratio of 16.98 percent. This suggests that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Avadel Pharmaceuticals PLC is more efficient with each dollar of assets it utilizes for everyday operations.Avadel Pharmaceuticals Ownership Allocation
Avadel Pharmaceuticals holds a total of 96.27 Million outstanding shares. The majority of Avadel Pharmaceuticals PLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Avadel Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Avadel Pharmaceuticals. Please pay attention to any change in the institutional holdings of Avadel Pharmaceuticals PLC as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Avadel Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 27.96 M. Net Loss for the year was (160.28 M) with profit before overhead, payroll, taxes, and interest of 16.59 M.About Avadel Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Avadel Pharmaceuticals PLC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Avadel Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Avadel Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Avadel Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Avadel Pharmaceuticals. We calculate exposure to Avadel Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Avadel Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 27.1 M | 38.8 M | |
| Pretax Profit Margin | (6.61) | (6.28) | |
| Operating Profit Margin | (5.67) | (5.39) | |
| Net Loss | (6.59) | (6.26) | |
| Gross Profit Margin | 0.87 | 0.65 |
Avadel Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Avadel Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 80.2 M | |
| Forward Price Earnings | 17.3913 |
Avadel Pharmaceuticals Current Valuation Indicators
Avadel Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Avadel Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Avadel Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Avadel Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Avadel Pharmaceuticals' worth.When determining whether Avadel Pharmaceuticals is a strong investment it is important to analyze Avadel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Avadel Pharmaceuticals' future performance. For an informed investment choice regarding Avadel Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.